Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2013. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding increases in their ordinary shareholdings.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes
On October 7, 2013, several directors and executives increased their holdings in GlaxoSmithKline plc ordinary shares. These increases resulted from the re-investment of dividends paid to shareholders on October 3, 2013. The shares were purchased at a price of 1,566.36 pence per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The content is limited to the disclosure of specific share transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the share price of 1,566.36 pence per share on October 7, 2013.
- Confirm the dividend payment date of October 3, 2013, and the reinvestment mechanism.
- Review the specific share count increases for key executives, including Sir Andrew Witty (878,465 shares) and Mr. S A Hussain (1,144,938 shares).
- Check subsequent filings for broader financial performance data not included in this transaction notice.